Tonix Pharmaceuticals Secures Second GPO Agreement for TONMYA, Expanding Coverage to 52M Lives

Tonix Pharmaceuticals announced a second commercial payer agreement effective June 1, 2026, adding approximately 17 million U.S. lives in coverage for its fibromyalgia drug TONMYA, bringing total commercial coverage to ~52 million lives (29% of U.S. commercial market). The milestone strengthens market access for TONMYA, the first new fibromyalgia treatment approved in over 15 years, as the company expands distribution through major group purchasing organizations.